Table 2.

Efficiency of compounds for peripheral targeting.

Target	Parasite species	Compound name	Effect on protein	Effect on parasite	Cell stage in vitro	Effect in vivo	Host species	Reference
HT	Plasmodium spp.	TCMDC-125163	IC50 39 nM	IC50 1.24 μM	Trophozoites	–	–	Ortiz et al., 2015
		C3361	Ki 8.6–53 μM	IC50 15–16 μM	Trophozoites	–	–	Joet et al., 2003; Blume et al., 2011
			–	IC50 11 μM	Liver-stage	–	Human	Slavic et al., 2011
HT1	B. bovis		Ki 4.1 μM	No inhibition at 100 μM	Trophozoites	–	–	de Muylder et al., 2011
GT1	T. gondii		Ki 82 μM	No inhibition at 200 μM	Tachyzoites	–	–	Blume et al., 2011
FNT	P. falciparum	MMV007839	IC50 0.02–0.17 μM	IC50 0.14 μM	Trophozoites	–	–	Golldack et al., 2017; Hapuarachchi et al., 2017
		MMV000972	IC50 0.05–0.17 μM	IC50 1.70 μM	Trophozoites	–	–
PT0	T. brucei	UK5099	Inhibition at 250 μM	–	–	–	–	Sanchez, 2013
PAT12	T.cruzi	Isotretinoin	–	IC50 0.13 μM	Epimastigotes	–	–	Reigada et al., 2017
				IC50 30.6 μM	Trypomastigotes	–	–
ENT1	Plasmodium spp.	ChemBridge 9001893 ChemBridge 6946484	IC50 2.5–30 nM	IC50 3–55 μM	Trophozoites	–	–	Frame et al., 2015b
ATP4	P. falciparum	Cipargamin	–	IC50 0.5–1.4 nM	Trophozoites	Clearance with 3-day dosing, 30 mg per day	Human	Rottmann et al., 2010; Spillman and Kirk, 2015
		SJ733	–	IC50 30 μM	Trophozoites	–	–	Spillman and Kirk, 2015
Calcium channels	Leishmania spp. Trypanosoma spp.	1,4-dihydropyridines (e.g., Nifedipine)	−−	IC50 2.6–181 μM	Promastigotes/Amastigotes Trypomastigotes	−−	−−	Tempone et al., 2009 Reimão et al., 2010, 2011
	A. castellanii	Amlodipine	–	Large inhibition at 1.2 μM	Trophozoites	–	–	Baig et al., 2013
	L. infantum	Non-dihydropyridines (e.g., fendiline)	–	IC50 2–16 μM	Promastigotes	–	–	Reimão et al., 2016
	T. cruzi		–		Epimastigotes	–	–	Reimão et al., 2016
K1/K2	T. brucei	Fluticasone	IC50 0.7 μM	–	–	–	–	Schmidt et al., 2017